Sol-Gel Technologies (SLGL) Interest Expenses (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Interest Expenses of $58.5 million for Q4 2025, up 17.5% year-over-year from $49.8 million in Q4 2024, and up 15418.3% quarter-over-quarter from $377000.0 in Q2 2025.
Analysis
Sol-Gel Technologies (SLGL) Interest Expenses (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Interest Expenses for 10 consecutive years, with $58.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses rose 17.5% year-over-year to $58.5 million; the TTM figure through Mar 2026 stood at $377000.0 (up 18.18% YoY), while the FY2025 annual figure was $58.5 million, up 17.5% from the prior year.
- Interest Expenses improved to $58.5 million in Q4 2025 per SLGL's latest filing, from $377000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $58.5 million in Q4 2025 and bottomed at $319000.0 in Q2 2024.
- Historically, Interest Expenses has averaged $28.9 million across 5 years, with a median of $44.7 million in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 10854.41% — and 2024, when it gained 3.92%.
- Sol-Gel Technologies' Interest Expenses stood at $408000.0 in 2021, then jumped by 10854.41% to $44.7 million in 2022, then climbed by 7.2% to $47.9 million in 2023, then advanced by 3.92% to $49.8 million in 2024, then gained by 17.5% to $58.5 million in 2025.
- Business Quant data shows SLGL's Interest Expenses at $58.5 million in Q4 2025, $377000.0 in Q2 2025, and $49.8 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Sol-Gel Technologies | 195.40 Mn | 147.47 Mn | - | 481,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 481,000.00 |
| Jun 30, 2025 | 380,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Jun 30, 2022 | 329,000.00 |
| Jun 30, 2021 | 9,000.00 |
| Jun 30, 2020 | 481,000.00 |
| Jun 30, 2019 | 359,000.00 |
| Jun 30, 2018 | 379,000.00 |